Nitroxyl: a vasodilator of human vessels that is not susceptible to tolerance

Clinical Science
Karen L AndrewsJaye P F Chin-Dusting

Abstract

Pre-clinical studies have identified nitroxyl (HNO), the reduced congener of nitric oxide (NO•), as a potent vasodilator which is resistant to tolerance development. The present study explores the efficacy of HNO in human blood vessels and describes, for the first time, a vasodilator for humans that is not susceptible to tolerance. Human radial arteries and saphenous veins were obtained from patients undergoing coronary artery graft surgery and mounted in organ baths. Repeated vasodilator responses to the HNO donor Angeli's salt (AS) and NO• donor glyceryl trinitrate (GTN) were determined. AS- and GTN-induced concentration-dependent vasorelaxation of both human radial arteries (AS pEC50: 6.5 ± 0.2; -log M) and saphenous veins (pEC50: 6.7 ± 0.1) with similar potency. In human radial arteries, GTN-induced relaxation was reduced by the NO• scavenger hydroxocobalamin (HXC; P<0.05) but was unaffected by the HNO scavenger L-cysteine. Alternately, AS was unaffected by HXC but was reduced by L-cysteine (5-fold shift, P<0.05). The sGC (soluble guanylate cyclase) inhibitor ODQ abolished responses to both AS and GTN in arteries and veins (P<0.05). Inhibition of voltage-dependent potassium channels (Kv channels) with 4-AP also significantl...Continue Reading

References

Mar 15, 1989·Journal of the American College of Cardiology·H DeMots, S P Glasser
Oct 1, 1993·Clinical and Experimental Pharmacology & Physiology·C G Li, M J Rand
Aug 24, 1999·British Journal of Pharmacology·T MünzelA Mülsch
Apr 25, 2000·Clinical and Experimental Pharmacology & Physiology·N Marsh, A Marsh
Sep 26, 2000·The Journal of Thoracic and Cardiovascular Surgery·S VermaT J Anderson
May 18, 2001·American Journal of Physiology. Heart and Circulatory Physiology·C A HamiltonA F Dominiczak
Aug 23, 2001·Proceedings of the National Academy of Sciences of the United States of America·N PaolocciD A Kass
Apr 22, 2003·Proceedings of the National Academy of Sciences of the United States of America·Nazareno PaolocciDavid A Kass
May 14, 2003·Hypertension·Jennifer C IrvineBarbara K Kemp-Harper
Jul 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·Katrina M MirandaDavid A Wink
May 24, 2006·Cardiovascular Research·Yongde ZhangLuke J Janssen
Dec 27, 2006·Cardiovascular Research·Joanne L Favaloro, Barbara K Kemp-Harper
Feb 21, 2007·Hypertension·Jennifer C IrvineBarbara K Kemp-Harper
Dec 7, 2007·Journal of the American College of Cardiology·Ulrich HinkThomas Munzel
Oct 7, 2008·Trends in Pharmacological Sciences·Jennifer C IrvineBarbara K Kemp-Harper
Mar 3, 2009·American Journal of Physiology. Heart and Circulatory Physiology·Joanne L Favaloro, Barbara K Kemp-Harper
Apr 3, 2009·British Journal of Pharmacology·Karen L AndrewsBarbara K Kemp-Harper
Aug 3, 2010·Antioxidants & Redox Signaling·Michelle L BullenBarbara K Kemp-Harper
May 18, 2011·Circulation·Thomas MünzelTommaso Gori
Aug 2, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Michelle L BullenBarbara K Kemp-Harper
Dec 6, 2012·The Journal of Pharmacology and Experimental Therapeutics·Sonia DonzelliMichael Graham Espey
Jul 16, 2013·American Journal of Physiology. Heart and Circulatory Physiology·Jennifer C IrvineRobert E Widdop
Oct 11, 2013·Circulation. Heart Failure·Hani N SabbahDavid A Kass

❮ Previous
Next ❯

Citations

Sep 29, 2015·Antioxidants & Redox Signaling·V Thao-Vi DaoHarald H H W Schmidt
Jul 2, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Nicola KahlbergChen Huei Leo
Aug 11, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Yebo ZhouJin-Song Bian
Jan 12, 2017·Naunyn-Schmiedeberg's Archives of Pharmacology·Marianne TareBarbara K Kemp-Harper
Jun 19, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Francisco J Luna-VázquezMoustapha Bah
Dec 8, 2015·Oxidative Medicine and Cellular Longevity·B V Nagpure, Jin-Song Bian
May 10, 2019·Heart Failure Reviews·Yanqing GuoJian An
Jun 9, 2020·Frontiers in Pharmacology·Anida VelagicBarbara K Kemp-Harper
Jan 16, 2016·Oxidative Medicine and Cellular Longevity·Mai E Shoman, Omar M Aly
May 28, 2016·Clinical Science·Karen L AndrewsJaye P F Chin-Dusting
Nov 3, 2017·Medicinal Research Reviews·Catarina OliveiraFernanda Borges
Apr 5, 2020·International Journal of Molecular Sciences·Martin KadlecEliana Pintus
Jun 27, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sona CacanyiovaAndrea Berenyiova
Sep 1, 2017·Scientific Reports·Sonia DonzelliFriederike Cuello
Dec 24, 2018·International Journal of Molecular Sciences·Amaal Eman AbdulleDouwe J Mulder
Dec 22, 2015·Coordination Chemistry Reviews·Debashree BasudharDavid A Wink
Jul 9, 2021·Fitoterapia·Christian J Valencia-GuzmánCésar Ibarra-Alvarado
Jul 17, 2021·Cardiovascular Research·Alexandra PetrainaHarald H H W Schmidt
Aug 24, 2017·European Journal of Pharmacology·Brandi M WynneR Clinton Webb
Nov 30, 2021·Journal of Cardiovascular Pharmacology·Barbara Kemp-Harper

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.